- Home
- CRVS vs ATXS Comparison
CRVS vs ATXS Comparison
Compare CRVS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVS | ATXS |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.0M | 732.4M |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRVS | ATXS |
|---|---|---|
| Price | $7.69 | $13.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | $13.75 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $3.56 |
| 52 Week High | $9.60 | $13.29 |
Technical Indicators
Market Signals| Indicator | CRVS | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 65.77 |
| Support Level | $7.28 | $12.64 |
| Resistance Level | $7.86 | $13.03 |
| Average True Range (ATR) | 0.42 | 0.20 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 29.01 | 95.00 |
Price Performance
Historical ComparisonAbout CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.